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INTRODUCTION
Parkinson’s Disease (PD) is the most common progressive neurode­
generative movement disorder which affects around 6 million people 
globally and the prevalence will rise with an aging population.1,2 Majority 
of the cases of PD are still considered idiopathic. There are some hypo­
theses of neuronal loss which involves genetically linked factors and 
environmental interaction factors. Ingestion or inhalation of neurotoxins 
(1­methyl­4­phenyl­1,2,3,6­tetrahydropyridine [MPTP]), endogenous 
toxin releasing radical oxygen species (ROS) in brain and isoquinoline 
derivatives substances may cause PD.3 
Although various therapeutic agents are available to cure PD symptom­
atically, there are many adverse effects associated with those medications. 
Taken levodopa as an example, even though it remains the pharmacologic 
mainstay for the treatment of PD,4 after several years of favorable 
responses, disabling motor complications frequently developed.5 Other 
than that, numerous side effects and complications of other dopami­
nergic medications and surgery had been testified too.6,7 So, these have 
reached our consensus that, till date, none of the drug or therapies has 
been convincingly shown to halt or cure the degenerative process in PD.
In light of these challenges, researches into alternative neuro­protective 
therapies area are rising at a feverish pace. Increasing number of patients 
are seeking for alternative treatments such as herbal therapies.8 Many 
researchers had discovered the broad therapeutic potential of a mushroom 
species Ganoderma lucidum (Family: Ganodermataceae). Among the 
bioactive elements in G. lucidum, polysaccharides, triterpenes, and 
peptidoglycans are three major physiologically active constituents in 
G. lucidum.9,10 G. lucidum polysaccharides (GLPS) obtained by aqueous 
extraction are reported to exhibit a wide­ranging bioactivities, including 
anti­inflammatory, hypoglycemic, anti­ulcer, anti­tumorigenic, and 
immunostimulating effects.11,12 On the other hand, the triterpenoids extract 
of G. lucidum (GLTT) by methanolic extraction demonstrated antipruritic 
effects13 and anti­cancer properties14,15 Previous studies which stated that 
the extract of G. lucidum is effective to improve the function of mito­
chondria in aged rat brain, suggested it as a possible therapeutic appli­
cation against ageing­associated neurodegenerative diseases.16 Of this 
interest, we hypothesize that G. lucidum extract has its therapeutic 
efficacy on PD. By using MPTP, PD was induced to Swiss albino mice, 
after which the effects of G. lucidum polysaccharide (GLPS) and triterpenoid 
(GLTT) fractions were investigated.
MATERIALS AND METHODS
G. lucidum was gifted by DXN Pharma Sdn Bhd., Malaysia. 1­methyl­
4­phenyl­1,2,3,6­tetrahydropyridine (MPTP) was obtained from Sigma 
Aldrich Co, St. Louis, USA. All chemicals, consumables and solvents 
used in this project were of analytical grade and purchased from 
Bendosen laboratory chemicals, Malaysia. EDTA, diethyl ether and form­
aldehyde were procured from RM chemicals/ HmbG chemicals, Malaysia.
Animals
Healthy, adult, both the gender of Swiss albino mice weighing 20­30 g 
were obtained from Central Animal house, AIMST University, Malaysia. 
The animals were housed in large, spacious poly acrylic cages at an ambient 
room temperature with 12 h light and dark cycle. The animals were fed 
with water and food ad libitum. The PD induced animal model study 
was approved by AIMST University Human and Animal Ethics Commi­
ttee and the study was conducted according to Animal Research Review 
Panel guidelines.
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ABSTRACT
Objectives: To investigate the behavioral effect of Ganoderma lucidum 
polysaccharides (GLPS) and triterpenoid fractions (GLTT) in Parkinson’s 
induced mice. Methods: Parkinson’s disease (PD) was induced by intra-
peritoneal administration of of 3 mg/kg 1-methyl-4-phenyl-1,2,3,6-tetrahy-
dropyridine (MPTP). G. lucidum was collected, authenticated and extracted 
with water and methanol to obtain GLPS and GLTT extracts respectively. 
A dose of 50 mg/kg of GLPS and GLTT were administered orally to PD mice 
for five consecutive days. Behavioral studies such as forced swim test, 
rota-rod test, grip strength test and locomotor activity were conducted 
in all the animals before and after toxicant, GLPS and GLTT treatment. 
Results: The mice injected with MPTP induced reasonable extent of 
Parkinsonism. In forced swim test, after treatment with GLPS and GLTT, 
the time for the mice to stop swimming decreased. In grip strength test, 
the motor coordination of PD induced mice seemed to be higher when 
compared to the normal mice, GLPS and GLTT treated groups. In rota-rod 
test, treatment with GLPS and GLTT showed mild decrease in the time 
for the mice to fall from a rotating rod. The results of the locomotor test 
showed that the mice had an increase in its locomotor activity after being 
induced with MPTP and decreased after being treated with GLPS and 
GLTT. Conclusion: This preliminary study results indicate that both GLPS 
and GLTT extract has therapeutic benefit on the PD mice.
Key words: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), Anti-
parkinsonism activity, Ganoderma lucidum, Polysaccharide, Triterpenoid. 
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Extraction of GLPS and GLTT 
G. lucidum was extracted with distilled water by maceration in a dark 
place for 6 days. Few drops of 1% chloroform were used as preserva­
tive to prevent fungal growth. Later, the extract was filtered and dried at 
60˚C. The semisolid form of G. lucidum polysaccharide (GLPS) extract 
was preserved in cold conditions until further studies.
For the triterpenoid extraction, G. lucidum powder extracted with methanol 
by Soxhlet extraction for 24 h. The extract was evaporated to dryness 
on a rotary evaporator to obtain G. lucidum triterpenoid (GLTT). The 
extract was stored in cold conditions until further studies.
Antiparkinson activity of GLPS and GLTT 
Healthy Swiss albino mice were divided into five groups each of five 
animals as follows. 
Group I : Control
Group II : MPTP control
Group III : MPTP+GLPS 50 mg/kg
Group IV : MPTP+GLTT 50 mg/kg 
A control group animal were administered with normal saline (1 ml/
kg) and the animals in group II to IV were administered with 3 mg/
kg MPTP (dissolved in saline), intraperitoneally for 5 consecutive days. 
After induction of PD, the animals in group III and IV were treated with 
GLPS (50 mg/kg) and GLTT (50 mg/kg). The drugs were suspended with 
0.5% carboxymethyl cellulose and administered orally for 5 consecutive 
days. During the experiment, body weight variations, regular food and 
water intake was measured. Prior to the experiment and at the end of 
the experi ment, the rats’ behavior was studied using forced swim test, 
grip strength test, rota­rod test and locomotor activity.17,18 At the end of 
the study the rats were sacrificed and brain samples were collected and 
preserved in 10% neutral formalin for histopathological studies.
Forced swim test: In this test, the tank with water of temperature 
24°C­30°C with depth that the rodent’s tails and feet not touching the 
bottom of the tank was prepared. The rodent was then put into the tank 
upon which the time between the rodent to stop swimming and start 
sinking was recorded. The rodent was removed immediately as soon as it 
started to sink. The procedure was repeated for all the rodents. The water 
tank was then cleaned as the accumulation of faeces and urine could 
cause bacterial contamination.
Grip strength test: The forelimb of the rodent was left to cling on a rope 
while its body and tail was suspended in the air above 50 cm from the 
ground. The time of the rodent clinging on the rope was recorded. The 
procedure was repeated for all 5 rodents of both control and treated 
group. The height between the rope and ground was ensured not be too 
high, to prevent the rodent hurt when falling. 
Rota-rod test: The rodent was placed on a rota­rod with speed of 20 
RPM. The time between rodent maintain on the rota­rod until it fall was 
recorded. The procedure was repeated for each rodent. 
Locomotor activity: The locomotor activity of the rats was recorded in 
actophotometer provided with an acrylic cage and 8 beams of infrared 
light along both the x­ and y­axis. The activity of each rat was monitored 
at room temperature over 10 min.
Histopathological analysis
The brain samples were preserved in 10% neutral formalin for histo­
pathological analysis. The brain sample were embedded in paraffin after 
being dehydrated in alcohol and subsequently cleared with xylene. 
A 5­6 micrometer thickness of brain section were prepared from par­
affin blocks and stained with hematoxylin and eosin and mounted in 
neutral DPX medium, and the sections were examined under light 
microscope.
Statistical analysis
All statistical data are represented as mean ± SEM of the mentioned 
number of testing in five animals. One way ANOVA (Graph Pad Prism 
5.00, Instat software, San Diego, CA< USA) followed by Tukey’s post hoc 
test were used for the statistical analysis.
RESULT 
The semisolid form of G. lucidum polysaccharide (GLPS) and triterpenoid 
(GLTT) extracts were used in this study. The percentage yield of GLPS 
and GLTT were found to be 8.88% and 6.67% respectively. 
The effect of GLPS and GLTT extract on MPTP induced behavioral 
alterations were summarized in Table 1. On day of termination MPTP 
treated animals showed increased swimming ability, muscular strength, 
and increased locomotor activity. Whereas GLPS and GLTT significant­
ly inhibited the MPTP induced behavioral alterations. No significant 
alteration was observed in rota­rod test. Histopathological analysis did 
not indicate any abnormality in the brain tissue of GLPS and GLTT treat­
ed animals (Figure 1).
DISCUSSION 
Parkinson’s disease is characterized by the tetrad of tremor at rest, 
rigidity, decreased voluntary movements, and postural instability due 
to depletion of dopamine levels in nigrostriatal system and loss of neu­
rons of nigrostriatal dopaminergic pathway. loss of dopamine producing 
neurons in the nigrostriatal system. The mice were injected with MPTP 
to induce PD, because the pathogenesis of MPTP induced PD in mice 
is clearly linked to a form of human parkinsonism.19,20 Since GLPS and 
GLTT, has combination benefit without toxicity which represents the 
desired end results in the development of effective therapeutics interven­
tions, it has been used for hundreds of years as a health promotion and 
treatment strategy.21,22
In the present study, MPTP administered group showed an increased 
neuronal and muscular activities rather than a decrease. PD was char­
Table 1: Behavioral studies of PD induced mice models before and after GLPS and GLTT treatment
Behavioral Tests
Baseline
(seconds)
1st day
after MPTP
(seconds)
5th day
after MPTP
(seconds)
GLPS 50 mg/kg
 (seconds)
GLTT 50 mg/kg
 (seconds)
Forced Swim Test 84.00 ± 1.44 118.00 ± 4.98 158.20 ± 5.51 57.20 ± 9.83 60.50 ± 6.10
Grip Strength Test 89.20 ± 1.48 120.20 ± 4.73 160.80 ± 5.20 81.60 ± 4.40 90.10 ± 5.40
Rota-rod Test 25.60 ± 3.65 25.20 ± 1.37 29.10 ± 2.57 17.70 ± 3.39 19.50 ± 2.84
Locomotor activity 79.00 ± 1.12 118.00 ± 2.00 136.00 ± 1.77 108.00 ± 4.12 142.00 ± 2.98
*The values are mean ± SEM of five animals.
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ABBREVIATIONS USED
PD: Parkinson’s disease; MPTP: (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine ); GLPS: Ganoderma lucidum polysaccharides; GLTT: Ganoderma lucidum  
triterpenoid; ROS: Radical oxygen species.
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Figure 1(A): A Section from the brain of a normal animal which shows partial 
distruction of neuronal cells. H and E, ×100.
Figure 1(B): A Section from the brain of an MPTP adminsited animals shows 
partial distruction of neuronal cells. H and E, ×100.
acterized by a decreased voluntary movement, but we observed an 
increased motor activity after MPTP administration and this may be due 
to its sympathomimetic over activation or frequency of MPTP which 
may not be sufficient to induce PD in experimental animals. Porras 
et al induced PD in monkey and mouse and they found that “MPTP 
mouse models for instance failed to replicate symptomatic manifesta­
tion of PD”.22 GLPS and GLTT were found to alter the MTPT induced 
increase in behavioral function and this indicates that both GLPS and 
GLTT has some degree of neuroprotective effect. Zhang et al., and Zhou 
et al., studied the neuroprotective effect of G. lucidum and the effect is 
due to reduction in the percentage of apoptotic neurons, suppressed 
overexpression of active caspasses­3, ­8 and ­9, myeloperoxidase activity, 
malondialdehyde levels, nitric oxide levels and inhibition of the reduc­
tion of Bcl­2 expression.23,24
CONCLUSION
The mice models injected with MPTP successfully induced reasonable 
extent of Parkinsonism. After employing GLPS and GLTT into the PD 
induced mice models, the behavioral studies of forced swim test and grip 
strength test reflected mean values which indicated that GPLS and GLTT 
held therapeutic benefit on the mice models, when compared with control.
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